跳转至内容
Merck
CN

PZ0321

WYE-125132

≥97% (HPLC)

别名:

N-[4-[1-(1,4-Dioxaspiro[4.5]dec-8-yl)-4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]-N′-methyl-urea, WYE-132

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C27H33N7O4
化学文摘社编号:
分子量:
519.60
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥97% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

N6(CC7OC(C6)CC7)c1nc(nc3[n](ncc31)C4CCC5(OCCO5)CC4)c2ccc(cc2)NC(=O)NC

InChI

1S/C27H33N7O4/c1-28-26(35)30-18-4-2-17(3-5-18)23-31-24(33-15-20-6-7-21(16-33)38-20)22-14-29-34(25(22)32-23)19-8-10-27(11-9-19)36-12-13-37-27/h2-5,14,19-21H,6-13,15-16H2,1H3,(H2,28,30,35)

InChI key

QLHHRYZMBGPBJG-UHFFFAOYSA-N

Biochem/physiol Actions

In ovarian cancer cells, WYE-132 might prevent the activity of sphingosine kinase-1 (SphK1), leading to pro-apoptotic ceramide production.
WYE-125132 (WYE-132) is a highly potent, ATP-competitive, and specific inhibitor of mTOR with an IC50 value of 0.19 nM. Unlike rapamycin, which ihibits mTOR through allosteric binding to mTOR complex 1 (mTORC1) only, WYE-132 inhibits both mTORC1 and mTORC2. WYE-125132 is >5000-fold selective for mTOR vs. phosphoinositide 3-kinase (PI3K). WYE-132 induced apoptosis in a variety of cancer lines including LNCap prostate cells and H1975 lung cancer cells. WYE-132 also inhibited ovarian cancer cell growth.


存储类别

11 - Combustible Solids

wgk

WGK 3



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Feiran Lu et al.
eLife, 4 (2015-12-10)
Niemann-Pick C1 (NPC1) is a lysosomal membrane protein that exports cholesterol derived from receptor-mediated uptake of LDL, and it also mediates cellular entry of Ebola virus. Cholesterol export is inhibited by nanomolar concentrations of U18666A, a cationic sterol. To identify
Sameer S Chopra et al.
Cell systems, 10(1), 66-81 (2019-12-10)
Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare. As a result, many cancers with high PI3K pathway activity, such as triple-negative breast cancer (TNBC), are treated



全球贸易项目编号

货号GTIN
PZ0321-5MG04061832449586
PZ0321-25MG04061832449579